about
Recent advances in the development of Aurora kinases inhibitors in hematological malignanciesA phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Mitosis as an anti-cancer drug target.
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
ENMD-2076 for hematological malignancies.
@en
ENMD-2076 for hematological malignancies.
@nl
type
label
ENMD-2076 for hematological malignancies.
@en
ENMD-2076 for hematological malignancies.
@nl
prefLabel
ENMD-2076 for hematological malignancies.
@en
ENMD-2076 for hematological malignancies.
@nl
P2860
P1476
ENMD-2076 for hematological malignancies.
@en
P2093
Jonathan How
P2860
P304
P356
10.1517/13543784.2012.668882
P407
P577
2012-03-08T00:00:00Z